| Literature DB >> 29220698 |
Francesco Bellanti1, Rosanna Villani1, Rosanna Tamborra1, Maria Blonda2, Giuseppina Iannelli1, Giorgia di Bello1, Antonio Facciorusso1, Giuseppe Poli3, Luigi Iuliano4, Carlo Avolio5, Gianluigi Vendemiale1, Gaetano Serviddio6.
Abstract
The complete mechanism accounting for the progression from simple steatosis to steatohepatitis in nonalcoholic fatty liver disease (NAFLD) has not been elucidated. Lipotoxicity refers to cellular injury caused by hepatic free fatty acids (FFAs) and cholesterol accumulation. Excess cholesterol autoxidizes to oxysterols during oxidative stress conditions. We hypothesize that interaction of FAs and cholesterol derivatives may primarily impair mitochondrial function and affect biogenesis adaptation during NAFLD progression. We demonstrated that the accumulation of specific non-enzymatic oxysterols in the liver of animals fed high-fat+high-cholesterol diet induces mitochondrial damage and depletion of proteins of the respiratory chain complexes. When tested in vitro, 5α-cholestane-3β,5,6β-triol (triol) combined to FFAs was able to reduce respiration in isolated liver mitochondria, induced apoptosis in primary hepatocytes, and down-regulated transcription factors involved in mitochondrial biogenesis. Finally, a lower protein content in the mitochondrial respiratory chain complexes was observed in human non-alcoholic steatohepatitis. In conclusion, hepatic accumulation of FFAs and non-enzymatic oxysterols synergistically facilitates development and progression of NAFLD by impairing mitochondrial function, energy balance and biogenesis adaptation to chronic injury.Entities:
Keywords: Cholesterol excess; Fatty acids; Mitochondria; Non-alcoholic fatty liver disease; Oxysterols
Mesh:
Substances:
Year: 2017 PMID: 29220698 PMCID: PMC5725223 DOI: 10.1016/j.redox.2017.11.016
Source DB: PubMed Journal: Redox Biol ISSN: 2213-2317 Impact factor: 11.799
Fig. 1Increased non-enzymatic oxysterol levels in the liver of HF+HCh-induced NASH. (A) Histological analysis of representative liver samples from rats fed a standard (CTRL), high-fat (HF) or high-fat+high-cholesterol (HF+HCh) diet, stained with Haematoxilin & Eosin (magnification 100x and 200x). (B) Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in all the animal groups studied. (C) Hepatic levels of the non-enzymatic oxysterols measured by mass spectrometry in all the groups studied. Data are expressed as mean ± SDM of five consecutive experiments. Statistical differences were assessed by one-way ANOVA and Tukey-Kramer as post-hoc test (* = p < 0.05 vs CTRL; ** = p < 0.01 vs CTRL; ^ = p < 0.05 vs HF; ^^ = p < 0.01 vs HF). 7 beta, 7β-hydroxycholesterol; 5b,6b-epoxy, 5β,6β-epoxycholesterol; 5a,6a-epoxy, 5α,6α-epoxycholesterol; triol, 5α-cholestane-3β,5,6β-triol; 7-keto, 7-ketocholesterol; 6-oxo, 6-oxo-cholestan-3β,5α-diol.
Kleiner scoring system applied to liver samples from rats fed a standard (CTRL), high-fat (HF) or high-fat+high-cholesterol (HF+HC) diet.
| 0 | 0 | 0 | 0 | Normal | |
| 3 | 0 | 1 | 4 | NAFL | |
| 2 | 2 | 2 | 6 | NASH |
Respiratory activity, Respiratory Control Index (RCI) and Membrane Potential (MMP) in isolated liver mitochondria from rats fed the standard (CTRL), high-fat (HF) or high-fat+high-cholesterol (HF+HC) diets for 6 weeks. Data are expressed as mean ± SDM of five consecutive experiments. Statistical differences were assessed by one-way ANOVA and Tukey-Kramer as post-hoc test (* = p < 0.05 vs CTRL, ^ = p < 0.05 vs HF).
| 2.5 ± 0.6 | 4.1 ± 1.3 | 4.4 ± 3.9 | ||
| 13.5 ± 2.3 | 13.3 ± 4.1 | |||
| 5.5 ± 0.4 | 3.9 ± 0.8 | |||
| 0.8 ± 0.1 | 1.0 ± 0.1 | 1.0 ± 0.1 | ||
| 14.3 ± 7.1 | 20.2 ± 3.9 | |||
| 31.8 ± 16.3 | 40.1 ± 11.4 | |||
| 2.2 ± 0.1 | 2.0 ± 0.7 | 1.77 ± 0.30 | ||
| 1.2 ± 0.2 | 1.2 ± 1.0 | 1.4 ± 0.1 | ||
| 59.3 ± 24.6 | 40.8 ± 10.8 | 78.9 ± 36.1 | ||
| 85.2 ± 30.4 | 80.3 ± 15.8 | 99.3 ± 34.8 | ||
| 172 ± 2 |
Fig. 2Hepatic ATP homeostasis and mitochondrial HOproduction rate impairment in HF+HCh-induced NASH. (A) Hepatic ATP content in rats fed a standard (CTRL), high-fat (HF) or high-fat+high-cholesterol (HF+HCh) diet for 6 weeks. (B) Complex V (ATPase) activity in all the groups studied. (C) hydrogen peroxide production rate in liver mitochondria from all the groups studied, using glutamate + malate (Complex I) or succinate in the presence of rotenone (Complex II) as oxidative substrates. Data are expressed as mean ± SDM of five consecutive experiments. Statistical differences were assessed by one-way ANOVA and Tukey-Kramer as post-hoc test. (* = p < 0.05 vs CTRL; ** = p < 0.01 vs CTRL; ^ = p < 0.05 vs HF; ^^ = p < 0.01 vs HF).
Fig. 3Increased mitochondrial uncoupling and UCP2 expression in NAFLD. (A) Proton leak kinetics in mitochondria isolated from rats fed a standard (CTRL), high-fat (HF) or high-fat+high-cholesterol (HF+HCh) diet for 6 weeks. The membrane potential dependence of the proton leak rate was determined in mitochondria oxidizing succinate (10 mM) in the presence of rotenone. Oligomycin was added to inhibit ATP synthase activity. The small figures show the proton permeability obtained after mitochondrial pre-incubation with the uncoupling proteins’inhibitor guanosine diposphate (GDP). The proton permeability was prevented by GDP in HF+HCh, but not in HF. (B) Gene expression of the Uncoupling Protein 2 (UCP2) measured by real time rt-PCR in the liver of all groups studied. (C) and (D) Densitometric analysis and representative blot of UCP2 immunoprecipitated in liver mitochondria proteins from all the groups studied. Data are expressed as mean ± SDM of five consecutive experiments. Statistical differences were assessed by one-way ANOVA and Tukey-Kramer as post-hoc test.
List of the genes up- or down-regulated (> 2 fold) in the HF (A) and HF+HC (B) groups with respect to CTRL. Changes in gene expression between groups were evaluated using RT2 Profiler 96-well PCR array plates. Data analysis was done by the 2-DDCt method on the manufacturer's Web portal (http://www.SABiosciences.com/pcrarraydataanalysis.php), (QIAGEN, CA, USA).
| A | |||
| Cox15 | Cytochrome c oxidase assembly protein (yeast) | 2,1936 | |
| Bcs1l | BCS1-like (yeast) | 4 | |
| Atp4a | ATPase, H+/K+ exchanging, alpha polypeptide | 2,1936 | |
| Atp12a | ATPase, H+/K+ transporting, alpha polypeptide | −3,4983 | |
| Atp4b | ATPase, H+/K+ exchanging, beta polypeptide | −3,4983 | |
| Atp5a1 | ATP synthase, mitochondrial F1 complex, alpha subunit 1 | −2,0093 | |
| Atp5b | ATP synthase, mitochondrial F1 complex, beta polypeptide | −2,4172 | |
| Atp5c1 | ATP synthase, mitochondrial F1 complex, gamma polypeptide 1 | −2,1535 | |
| Atp5i | ATP synthase, mitochondrial F0 complex, subunit e | −3,4983 | |
| Atp5j | ATP synthase, mitochondrial F0 complex, subunit F6 | −2,1043 | |
| Atp5l | ATP synthase, mitochondrial F0 complex, subunit G | −2,0093 | |
| Atp6ap1 | ATPase, H+ transporting, lysosomal accessory protein 1 | −2,1535 | |
| Atp6v1c2 | ATPase, lysosomal V1 subunit C2 | −3,4983 | |
| Atp6v1e2 | ATPase, lysosomal V1 subunit E2 | −3,4983 | |
| Bcs1l | BCS1-like (yeast) | −2,1043 | |
| Cox4i1 | Cytochrome c oxidase subunit IV isoform 1 | −2,4172 | |
| Cox5a | Cytochrome c oxidase, subunit Va | −2,1043 | |
| Cox6a2 | Cytochrome c oxidase subunit VIa polypeptide 2 | −3,4184 | |
| Cox6c | Cytochrome c oxidase, subunit Vic | −3,1895 | |
| Cox7a2 | Cytochrome c oxidase subunit VIIa polypeptide 2 | −2,2038 | |
| Cox7b | Cytochrome c oxidase subunit VIIb | −2,1535 | |
| Cox8c | Cytochrome c oxidase, subunit VIIIc | −3,4983 | |
| Lhpp | Phospholys phosphohistidine inorganic pyrophosp phosphatase | −4,9474 | |
| Ndufa1 | NADH dehydrogenase 1 alpha subcomplex, 1 | −3,0455 | |
| Ndufa11 | NADH dehydrogenase 1 alpha subcomplex 11 | −2,0562 | |
| Ndufa2 | NADH dehydrogenase 1 alpha subcomplex, 2 | −2308 | |
| Ndufb6 | NADH dehydrogenase 1 beta subcomplex, 6 | −2,0093 | |
| Ndufb7 | NADH dehydrogenase 1 beta subcomplex, 7 | −2,2553 | |
| Ndufb9 | NADH dehydrogenase 1 beta subcomplex, 9 | −2,5907 | |
| Ndufs2 | NADH dehydrogenase Fe-S protein 2 | −3,1895 | |
| Ndufs3 | NADH dehydrogenase Fe-S protein 3 | −2,2038 | |
| Sdhb | Succinate dehydrogenase complex, subunit B, iron sulfur | −2,2553 | |
| Sdhd | Succinate dehydrogenase complex, subunit D | −2,0093 | |
| Slc25a10 | Solute carrier family 25, member 10 | −2,2553 | |
| Slc25a15 | Solute carrier family 25, member 15 | −3,3404 | |
| Ucp1 | Uncoupling protein 1 | −3,4983 | |
| Ucp3 | Uncoupling protein 3 | −3,4983 | |
| Uqcrq | Ubiquinol-cytochrome c reductase, complex III subunit VII | −3,4983 | |
Fig. 4Co-treating primary hepatocytes with fatty acids and the oxysterol triol induces cell death. (A) Cell viability of rat primary hepatocytes after 24 incubation with palmitic acid (PA) ± oleic acid (OA) ± Triol, assessed by the MTT assay. Data are expressed as mean ± SDM of three consecutive experiments. Statistical differences were assessed by one-way ANOVA and Tukey-Kramer as post-hoc test. (B) Effect of 24 h incubation with Triol 10 µM, palmitic acid 50 µM + oleic acid 2 mM (PA+OA), or palmitic acid 50 µM + oleic acid 2 mM + Triol 10 µM (PA + OA + Triol) on rat primary hepatocytes aptoptosis and necrosis. Apoptotic or necrotic cells were detected by flow cytometry after staining with annexin V and 7-AAD. 50 µM PA and 2 mM OA were chosen as the highes non-toxic concentrations for the induction of cellular steatosis.
Fig. 5Mitochondrial function and biogenesis impairment in primary hepatocytes after co-treatment with fatty acids and the oxysterol triol. (A) Oxygen consumption rate of isolated liver mitochondria after incubation with increased concentrations of 5α-cholestane-3β,5,6β-triol (Triol) for 24 h. Mitochondrial respiration was started by pyruvate+malate and glutamate (Complex I) or succinate in the presence of rotenone (Complex II). Data are expressed as mean ± SDM of three consecutive experiments. Statistical differences were assessed by one-way ANOVA and Tukey-Kramer as post-hoc test (* = p < 0.05 vs CTRL, ** = p < 0.01 vs CTRL). (B) Representative oxygraphic measurement of intact hepatocytes respiration after 24 h incubation with palmitic acid (PA) + oleic acid (OA) ± Triol. (C) Mitochondrial/cellular respiratory rate measured in intact rat primary hepatocytes after 24 h incubation with PA+OA ± Triol. (D) Gene expression of peroxisome proliferator-activated receptor-γ coactivator 1 α (PGC1α), mitochondrial transcription factor A (TFAM) and nuclear respiratory factor 1 (NRF1) measured by real time rt-PCR in the rat primary hepatocytes after 24 h incubation with PA+OA ± Triol. Data are expressed as mean ± SDM of three consecutive experiments. Statistical differences were assessed by one-way ANOVA and Tukey-Kramer as post-hoc test.
Fig. 6Reduction of mitochondrial respiratory proteins and master regulators of biogenesis in human NASH. (A) Representative second dimension of a BN-PAGE performed on mitochondrial proteins isolated by the liver of healthy subjects (HEALTHY) and patients affected by simple steatosis (NAFL) or steatohepatitis (NASH). Bands characteristic of individual OXPHOS complexes are recognizable in all three experimental groups. Protein extracts were prepared for each patient, and each individual was assessed separately. Each lane contained 15 μg of mitochondrial protein extract. (B) Gene expression of peroxisome proliferator-activated receptor-γ coactivator 1 α (PGC1α), mitochondrial transcription factor A (TFAM) and nuclear respiratory factor 1 (NRF1) measured by real time rt-PCR in the liver of all patient groups studied. Data are expressed as mean ± SDM of 8+7+10 experiments. Statistical differences were assessed by one-way ANOVA and Tukey-Kramer as post-hoc test.